DuPont Reports 62% Adjusted EPS Jump in Q3 2026 and Raises Full Year Guidance Again

DuPont de Nemours exceeded its own third-quarter 2026 financial guidance and lifted its full-year outlook for the second consecutive quarter, posting adjusted earnings per share of $2.09 for the period ended September 30, a 62% increase from $1.29 in the same quarter of 2025. GAAP EPS from continuing operations came in at $1.24, up 77% from $0.70 a year earlier. CEO Lori Koch credited mid-single-digit organic growth, strong operating leverage, and disciplined capital allocation for the performance.

Organic sales growth reached 4% in DuPont's Healthcare and Water Technologies segment and 5% in Diversified Industrials. The company also raised its full-year 2026 adjusted EPS guidance, building on a prior increase made after the second quarter when the full-year midpoint was lifted to $7.24 per share with net sales forecast in a range of $7.16 billion to $7.19 billion.

November 3 was a broad earnings day across markets, with Q3 2026 results also reported by Teva Pharmaceutical, Williams Companies, Pfizer, BioNTech, Henry Schein, HNI Corporation, UDR, Willis Lease Finance, Innovative Industrial Properties, Boise Cascade, and more than a dozen other companies spanning healthcare, energy, real estate, and industrials.